10,952 Shares of Merck & Co., Inc. $MRK Purchased by Madrona Financial Services LLC

Madrona Financial Services LLC bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,952 shares of the company’s stock, valued at approximately $1,591,000.

A number of other institutional investors have also recently made changes to their positions in MRK. BlackRock Inc. increased its stake in Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after acquiring an additional 1,073,507 shares during the last quarter. State Street Corp raised its position in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares during the period. Wellington Management Group LLP raised its position in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Bank of America Corp DE raised its position in Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after purchasing an additional 2,969,856 shares during the period. Institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MRK shares. BMO Capital Markets raised their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, August 20th. Bank of America boosted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Wells Fargo & Company increased their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Leerink Partners increased their price target on Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Finally, Cantor Fitzgerald raised their price target on Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $151.92.

Merck & Co., Inc. Price Performance

MRK stock opened at $145.25 on Friday. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a 50-day moving average price of $146.98 and a 200 day moving average price of $130.17. The stock has a market cap of $358.35 billion, a PE ratio of 116.20, a P/E/G ratio of 6.74 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the prior year, the firm posted $2.13 EPS. The firm’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 2.64 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Richard Deluca sold 20,784 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the transaction, the executive vice president directly owned 134,703 shares in the company, valued at approximately $17,569,312.29. This represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.